Results 211 to 220 of about 70,006 (293)

[Avoidable mortality and colorectal cancer].

open access: yesGaceta sanitaria, 2007
Miguel, Gili   +2 more
openaire   +1 more source

Primary Tumor Resection in Patients With Unresectable Metastatic Colorectal Cancer: A Systematic Review and Meta‐Analysis

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This systematic review and meta‐analysis evaluated the role of primary tumor resection (PTR) in asymptomatic patients with unresectable metastatic colorectal cancer. Across 17 eligible studies including 9317 patients, PTR did not improve overall or progression‐free survival compared with chemotherapy alone.
Junpei Takashima   +3 more
wiley   +1 more source

A Machine Learning Model for Predicting Posthepatectomy Liver Failure After Hepatectomy With Extrahepatic Bile Duct Resection for Perihilar Cholangiocarcinoma: With and Without Indocyanine Green

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
Using machine learning‐based decision tree models, patients with perihilar cholangiocarcinoma undergoing major hepatectomy with extrahepatic bile duct resection were stratified according to the risk of posthepatectomy liver failure. Separate models were developed with and without indocyanine green data, enabling clinically interpretable preoperative ...
Yuki Homma   +11 more
wiley   +1 more source

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy